Immunophage Biotech

Immunophage Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of innovative immunotherapies for cancer and autoimmune diseases. The company utilizes its proprietary phage-based antibody discovery platform and advanced antibody engineering technologies to create a robust pipeline of therapeutic candidates. Its lead assets include IPG7236, a monoclonal antibody targeting CCR8, and IPG1094, which targets ROR1, both of which have entered clinical trials. Immunophage focuses on addressing unmet medical needs through the development of first-in-class and best-in-class biologics, including monoclonal and bispecific antibodies. Supported by prominent venture capital investors, the company is expanding its clinical footprint globally to bring transformative treatments to patients.